SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is currently seeing intense debate as investors weigh aggressive institutional Ethereum accumulation against significant share price underperformance compared to broader crypto markets. Community sentiment is deeply polarized, with many retail traders expressing frustration over Tom Lee's leadership and dilution tactics while bulls continue to focus on the long-term potential of asset tokenization and upcoming clarity legislation.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is seeing increased volatility and investor attention following reports that Berkshire Hathaway has exited its entire position in the stock. While some investors express concern over this abrupt move by a major institutional holder, many in the community view the resulting dip as a potential buying opportunity, emphasizing the company's long-term operational strengths and its ongoing integration of AI into daily workflows.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors prepare for upcoming clinical data presentations at the AUA Annual Meeting, with the community focused on the durability of CAN-2409 and its potential as a practice-changing therapy. Discussions center on the stock's long-term value, with active debates occurring between bulls anticipating a premium acquisition and bears citing concerns over cash runway and timing.

Trio-Tech International engages in the provision of third-party semiconductor testing and burn-in services. It operates through the following segments: Semiconductor Back-End Solutions (SBS) and Industrial Electronics. The SBS segment is focused on the sale of burn-in and reliability test equipment used in the back-end manufacturing processes of semiconductors. Its equipment includes burn-in systems, burn-in boards, and related equipment that is used in the testing of structural integrity of integrated circuits. The Industrial Electronics segment consists of designing, manufacturing, and distributing a range of tests, processes, and other equipment used in the manufacturing processes of customers in various industries in the consumer and industrial market. The company was founded in 1958 and is headquartered in Los Angeles, CA.

Trio-Tech International

Trio-Tech International is trending as investors draw comparisons to high-growth semiconductor testing peers, citing its exposure to AI and EV chip demand. The community is actively discussing the company's potential for a valuation re-rating, fueled by its recent revenue growth, expansion of testing capacity, and a relatively small market cap that amplifies volatility.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with mobility drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, and taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting carriers with shippers on its platform, and gives carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber Technologies is trending as investors digest a flurry of strategic partnerships and institutional accumulation, with recent filings showing heavy buying from prominent hedge funds. The community is actively debating the company's valuation versus its long-term potential in autonomous vehicle integration and travel, while closely monitoring technical price levels ahead of upcoming earnings.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

The iShares Silver Trust (SLV) is witnessing heightened volatility and intense social media debate, driven by a combination of macroeconomic inflationary pressures, geopolitical concerns, and emerging industrial demand for silver in AI data center infrastructure. The community is sharply divided between "stackers" who view recent price dips as a strategic buying opportunity and skeptics who interpret the erratic price action as evidence of market manipulation and the conclusion of the recent bullish trend.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Delta Air Lines is facing significant investor attention as market participants weigh strong travel demand against the escalating geopolitical risks in the Middle East and rising jet fuel costs. The community is actively debating whether the airline's premium-focused strategy and operational resilience can effectively buffer the margin pressures currently weighing on the broader airline sector.

Vistra Corp. is a holding company, which engages in the provision of electricity and power generation. It operates through the following segments: Retail, Texas, East, West, and Asset Closure. The Retail segment includes sale of electricity and natural gas to residential, commercial, and industrial customers. The Texas and East segments are involved in electricity generation, wholesale energy sales and purchases, commodity risk management activities, fuel production and fuel logistics management. The West segment represents the company's electricity generation operations in CAISO. The Asset Closure segment refers to the decommissioning and reclamation of retired plants and mines. The company was founded in 1882 and is headquartered in Irving, TX.

Vistra Corp

Vistra Corp is trending as investors react to potential federal initiatives aimed at forcing hyperscalers to fund massive new power capacity, with community sentiment split between viewing this as a long-term growth catalyst for infrastructure providers and expressing frustration over recent price volatility. Discussion is heavily focused on the stock's position as a core 'AI power' play, with many participants looking for buying opportunities during pullbacks and highlighting institutional confidence in the company's ability to supply the grid.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is currently trending as investors grapple with a bond market selloff, evidenced by the 30-year Treasury yield hitting 5% amid persistent inflationary concerns and high U.S. debt levels. The community remains deeply divided, with some betting on a "buy-and-hold" strategy at historic lows while others argue the sector remains "uninvestable" due to rising yields and an evolving Fed landscape.

Macy's, Inc. engages in the retail of apparel, accessories, cosmetics, home furnishings, and other consumer goods. The firm's brands include Macy's, Bloomingdale's, and Bluemercury. It offers men's, women's, and children's apparel, women's accessories, intimate apparel, shoes, cosmetics, fragrances, as well as home and miscellaneous products. The company was founded by Rowland H. Macy in 1858 and is headquartered in New York, NY.

Macy`s Inc

Macy's Inc

Macy's is generating significant attention ahead of its quarterly earnings release, with traders closely monitoring its store optimization plans and comparable sales trends. The community is actively debating whether the retailer's turnaround strategy can deliver meaningful bottom-line growth or if recent momentum will be undercut by macro-driven consumer hesitation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA...

Here's What Analysts Think About ADMA Biologics (ADMA)

Here's What Analysts Think About ADMA Biologics (ADMA...

Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic?

The average brokerage recommendation (ABR) for Adma Biologics (ADMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

New Strong Sell Stocks for May 14th

ADMA, AMTB and APOG have been added to the Zacks Rank #5 (Strong Sell) List on May 14th, 2026.

New Strong Sell Stocks for May 11th

ADMA, APTV and ASTE have been added to the Zacks Rank #5 (Strong Sell) List on May 11th, 2026.

Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA

Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About...

ADMA Q1 EPS Jumps 73% Y/Y, Revenues Slip, 2026 View Down

ADMA cuts its 2026 outlook after Q1 revenues slip amid IG market pressure, though Asceniv demand and margins stay strong.

<ul class="summary-bullets"><li>Earlier this year, Culper Research alleged channel stuffing and undisclosed related-party transactions at Adma.&nbsp;</li><li>Adma said on Wednesday that there is no evidence of any illegal activity at the company.&nbsp;</li><li>The firm also withdrew its previously issued long-term guidance.</li></ul>ADMA Biologics (ADMA) shares plunged 24% in after-hours trading on Wednesday following the release of disappointing first-quarter results that showed flat revenue and a sharp cut to full-year guidance amid intensifying competition in the U.S. immunoglobulin (IG) market.ADMA reported first-quarter 2026 total revenue of $114.5 million, essentially flat compared with $114.8 million in the year-ago period and well below Wall Street expectations of roughly $140 million.The top-line miss was driven by a steep decline in BIVIGAM sales, which fell 54% year-over-year to $15.4 million, while ASCENIV sales grew 28% to $97.5 million. Both ASCENIV and BIVIGAM are used to treat primary humoral immunodeficiency, a group of inherited disorders leading to low antibody production.Despite the revenue stall, profitability metrics improved markedly. Diluted earnings per share came in at $0.19, above the $0.11 reported in the corresponding quarter of 2025, and in line with Wall Street expectations.<h2 class="st-heading-2">Management Weighs In On Competition</h2>In a statement, President and CEO Adam Grossman acknowledged near-term challenges but emphasized underlying strength in ASCENIV demand.“During the first quarter, the market for U.S. plasma-derived therapies and immunoglobulin experienced increased competitive dynamics which, along with variability in distributor ordering patterns, created near-term topline pressures, particularly impacting BIVIGAM,” Grossman said.“Importantly, these dynamics were limited to distribution and inventory behavior and we believe do not reflect any deterioration in underlying ASCENIV demand, where fundamentals remained strong and continue to improve—with record utilization growth throughout the quarter.”Grossman described Q1 results as a likely “trough revenue baseline” caused by what the company views as a “temporary market dislocation.”<h2 class="st-heading-2">ADMA’s 2026 Guidance</h2>ADMA updated its 2026 financial outlook to reflect the evolving competitive landscape. The company now expects full-year revenue of $530 million to $560 million, down from prior guidance above $635 million, and adjusted core profit of $265 million to $300 million. It also withdrew its previously issued long-term guidance.The company attributed the softer outlook to sustained pricing pressure on standard IG products and changing competitive dynamics.<h2 class="st-heading-2">Short-Seller Report</h2>ADMA also addressed lingering investor concerns stemming from a Culper Research report earlier this year that <a href="https://stocktwits.com/news-articles/markets/equity/adma-stock-drops-after-culper-research-alleges-channel-stuffing/cZ3nq7uRI1i">alleged</a> channel stuffing and undisclosed related-party transactions. Culper alleged in a report that Adma’s reported growth is a “fiction driven more than entirely by a de facto channel stuffing scheme and an undisclosed related party distributor." Without the sales figure inflation, Culper estimated Adma's revenues declined 3% in 2025 as compared to the 20% growth reported.However, Adma said on Wednesday that its Audit Committee, assisted by independent forensic accountants and external counsel, completed a review and “concluded that ADMA has not engaged in any improper channel stuffing or any undisclosed related party transactions,” finding “no evidence of any illegal activity,” it said.<h2 class="st-heading-2">How Did ADMA Retail Traders React?</h2>On Stocktwits, retail sentiment around ADMA stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.A Stocktwits user said that investors who invest now at ‘peak negativity’ stand the chance to make a lot of money.<stembedurl>https://www.stocktwits.com/david999957/message/652525861</stembedurl>Another opined that it is just a “terrible luck” year for the company with the short seller report and market dislocation for Bivigam.<stembedurl>https://www.stocktwits.com/azv134/message/652522379</stembedurl><a href="https://stocktwits.com/symbol/ADMA">ADMA stock</a> has fallen 56% over the past 12 months. &nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/srpt-stock-plunges-after-hours-as-elevidys-demand-slumps-ceo-still-sees-return-to-growth/cZQzkcWReOx">SRPT Stock Plunges 7% After-Hours As Elevidys Demand Slumps — CEO Still Sees Return To Growth</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the ADMA Biologics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

ADMA Tumbles On Slashed Outlook As Short-Seller Aftermath Meets Competitive Headwinds  

In a statement, President and CEO Adam Grossman acknowledged near-term challenges but emphasized underlying strength in its therapy ASCENIV’s demand.

Equity

ADMA Biologics (NASDAQ:ADMA) Issues Quarterly Earnings Results, Meets Expectations

ADMA Biologics (NASDAQ:ADMA - Get Free Report) issued its quarterly earnings results on Wednesday. The biotechnology company reported $0.19 earnings per share for the quarter, meeting analysts' consensus estimates of $0.19. ADMA Biologics had a net margin of 28.80% and a return on equity of 37.52...

ADMA Biologics Q1 Earnings Call Highlights

ADMA Biologics (NASDAQ:ADMA) executives said the company delivered earnings growth and margin expansion in the first quarter of 2026 despite essentially flat total revenue, as strong demand for its immunoglobulin product ASCENIV offset a steep decline in standard IG product BIVIGAM amid what managem...

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

ADMA
Adma Biologics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest ADMA News

ADMAAdma Biologics Inc